Oxford Biomedica - Novartis extends commercial supply agreement
Oxford Biomedica (OXB) has announced the expansion of its commercial supply agreement with Novartis by five years. While expected, this removes any...
1.7k Views
Oxford Biomedica - Investing for future growth
Oxford Biomedica’s (OXB) interim results highlight strong operational and financial momentum to date. The Novo Holdings equity investment (£53.5m)...
927 Views
Oxford BioMedica - Validation achieved, growth expected
Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica (OXB) has become one of a...
98 Views
Oxford BioMedica - LentiVector platform expanding into haemophilia
Oxford BioMedica (OXB) has announced a collaboration and licence agreement with Bioverativ to develop gene therapy products for the treatment of...
87 Views
Kymriah approved - royalties to OXB assured
Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been approved by the FDA for...
128 Views